Apimeds Pharmaceuticals Us,'s ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Apimeds Pharmaceuticals Us,'s ROI in the second quarter of 2026?
Apimeds Pharmaceuticals Us, Inc. recorded a cumulative net loss of $-50 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -46.79%.

Within the Healthcare sector 122 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3551 to 3552.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	4784.11 %	-	267506.27 %	53705.33 %	-
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	124	142	154	8	10
Return On Investment (TTM)	-46.79 %	-41.44 %	-14.06 %	-120.19 %	-169.31 %
APUS's Overall Ranking	# 3552	# 3551	#	#	#
Seq. Investment Change TTM	36.22 %	84 %	894.72 %	95.89 %	-
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-50	-33	-6	-5	-4

APUS Company Profile >> Back to APUS Roi Comparisons >> See Annual APUS Return On Investment

Return On Investment APUS's Ranking
Within:	No.
Industry	# 34
Sector	# 123
Overall	# 3552

Return On Investment Statistics
High	Average	Low
-14.06 %	-34.1 %	-46.79 %
(Dec 31 2025)		(Jun 30 2026)

Financial Statements
Apimeds Pharmaceuticals Us,'s II. Quarter Investments	$ 124 Millions	APUS's Balance sheet
Apimeds Pharmaceuticals Us,'s II. Quarter Income	$ -20 Millions	Quarterly APUS's Income Statement
APUS's Income by Division		See APUS's Income by Division

APUS Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2023) 2024
Total Investments in Millions	154	0	0	0	0
Y / Y Investment Growth	481407.21 %	-	-	-	-
Net Income in Millions	-6	-1	0	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-3.91 %	-2437.93 %	-	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
APUS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for APUS's Competitors
Subscribers only: Roi for Apimeds Pharmaceuticals Us,'s Suppliers
Subscribers only: Return On Investment for APUS's Customers

Other Ratios
APUS's Roa	APUS's Inventory Turnover Ratio	APUS's Growth Rates	APUS's Dividend Statistics
	APUS's Profitability Ratios	APUS's Asset Turnover Ratio	APUS's Dividend Growth
APUS's Roe	APUS's Valuation Ratios	APUS's Financial Strength Ratios	APUS's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-12T06:29:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.